Loading
Crizotinib produced responses in 83 to 90 per cent of children with relapsed ALK-positive anaplastic large cell lymphoma, most of them complete.
A Children's Oncology Group study of the ALK inhibitor crizotinib given by mouth twice daily to 26 patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma and 14 with metastatic or inoperable ALK-positive inflammatory myofibroblastic tumour, with serial measurement of NPM-ALK fusion transcripts in ALCL.
The evidence behind the statement on the ALK-positive ALCL page that ALK inhibitors produce responses and are used especially in children and young adults.
Shares ALK-positive anaplastic large cell lymphoma and the tag lymphoma-evidence-entities.
Shares ALK-positive anaplastic large cell lymphoma and the tag lymphoma-evidence-entities.
Shares ALK-positive anaplastic large cell lymphoma and the tag lymphoma-evidence-entities.
Shares Crizotinib, ALK.
Shares Crizotinib, ALK.
Shares Crizotinib, ALK.
Shares Crizotinib, ALK.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/